INTRODUCTION
The worldwide prevalence of type 2 diabetes mellitus (T2DM) continues to rise dramatically, with Asian countries contributing more than half of the world's diabetic population [1, 2] . Currently, 7.2 million individuals aged between 20 and 79 years are affected by T2DM in Japan [1] . T2DM clinical practice guidelines by the American Diabetes Association [3] and International Diabetes Federation [4] suggest starting treatment with metformin unless contraindicated, followed by the addition of other oral antidiabetic drugs (OADs) if patients fail to achieve glycosylated hemoglobin (HbA1c) goal \7.0%. The Japan Diabetes Society (JDS) suggests starting pharmacotherapy with any OAD depending on the physiological status of the patient after diet and exercise failure [5] . Most of the Japanese patients with T2DM have a tendency to a low body mass index (BMI); and as insulin secretion deficiency plays a predominant role in disease pathology [6] , insulin secretagogues are the preferred first-line treatment option in Japan. Recently, Japanese patients with T2DM
are being increasingly treated with dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., vildagliptin) [7] , which increase insulin secretion from b-cells in a glucose-dependent manner [8] . Moreover, the progressive nature of the disease warrants treatment intensification with other antidiabetic agents having complementary mechanism of action to maintain glycemic control over long term [5] .
The mechanistic synergy between vildagliptin and metformin [8, 9] , and the efficacy and safety of vildagliptin added to metformin in Japanese patients with T2DM
inadequately controlled with metformin monotherapy has already been demonstrated [10] . However, the benefit of switching patients, who are treated with vildagliptin and require additional treatment, to vildagliptin and metformin has not been established. So far, no DPP-4 inhibitor/metformin single-pill combination (SPC) is available in Japan. Such a SPC has the additional benefit of a reduced pill burden, and potentially better compliance [11] .
Moreover, the efficacy of low-dose metformin [250 mg twice daily (bid)] has not been studied previously in a randomized trial setting in Japanese patients with T2DM. Accordingly, the current study was aimed to assess the efficacy and safety of vildagliptin/metformin SPC at doses of 50/250 and 50/500 mg in Japanese patients with T2DM inadequately controlled with diet, exercise and vildagliptin monotherapy. 
MATERIALS AND METHODS

Study Design
Statistical Analysis
Assuming a dropout rate of 5%, 171 patients were to be randomized in a ratio of 2:1 (vilda/ met 114; vilda/placebo: 57) to achieve the target reported as mean ± SE were analyzed using the analysis of covariance model, with treatment as a classification variable and baseline value as a covariate. The last observation carried forward method was used for imputing missing data.
Chi-squared test was used to assess and compare the proportion of responders in the two groups. Safety data were summarized descriptively by treatment for the safety analysis set which included all the patients who received at least one dose of the study drug.
Ethics and Good Clinical Practice
The independent Ethics Committee/
Institutional Review Board at each center reviewed and approved the study protocol. All procedures followed were in accordance with the ethical standards of the responsible 
RESULTS
Patient Disposition and Baseline Characteristics
A total of 171 patients were randomized (vilda/ met, n = 115; vilda/placebo, n = 56) of which 160 (93.6%) patients completed the study. The most common reasons for discontinuations were AEs in the vilda/met group (3.5%) and unsatisfactory therapeutic effectiveness in the vilda/placebo group (5.4%) (Fig. 2) . Patient demographics and baseline characteristics were comparable between the two treatment groups ( 
Efficacy
The mean HbA1c change over 14 weeks is shown in Fig. 3a . After 2 weeks, the mean HbA1c levels were lower in all vilda/met groups compared with the vilda/placebo group. At week 14, a statistically significant between-treatment difference in (mean ± SE)
HbA1c of -1.0 ± 0.1% (P\0.001), in favor of the vilda/met group was observed (both doses combined) ( Table 2 ). Statistically significant Data are expressed as mean ± standard deviation, unless specified otherwise BMI body mass index, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HbA1c glycosylated hemoglobin, MDRD modification of diet in renal disease, SPC single-pill combination, T2DM type 2 diabetes mellitus
The mean FPG over 14 weeks is shown in Fig. 4 
Safety
The overall safety profile is summarized in in the vilda/met and vilda/placebo groups, respectively).
Three patients reported SAEs: syncope and convulsion in one patient in the vilda/met 50/500 mg subgroup; epiglottitis and gastric cancer in one patient each in the vilda/placebo group. There were no deaths in the study. There were no hypoglycemic events reported in either group. Asymptomatic mild elevations in pancreatic enzymes were reported in six patients. However, none of the events were considered as AEs of acute pancreatitis by the investigator and all patients completed the study. Body weight remained constant in both the groups after 14 weeks of treatment:
?0.1 ± 0.1 kg (baseline, 69.5 ± 12.6 kg) in the vilda/met group and ?0.2 ± 0.2 kg (72.1 ± 11.3 kg) in the vilda/placebo group. [10] . Almost half of patients treated with vilda/met SPC achieved the JDS recommended glycemic target of HbA1c\7.0% [5] with three-fourths of patients demonstrating a clinically relevant drop in HbA1c (C0.5%) [12] , thus, highlighting the benefit of switching patients who are inadequately controlled with vildagliptin monotherapy to the vildagliptin/ metformin SPC. The mean reduction in FPG levels was also significantly higher for the vilda/ met group compared with the vilda/placebo group, which is consistent with the mechanism of action of metformin to decrease the overnight hepatic glucose production [13] . The data presented here are the first data to establish the clinical efficacy of metformin 250 mg bid in Japanese patients, as such closing an important gap. Even this low metformin dose resulted in Table 2 ANCOVA results for change in HbA1c (%) from baseline to endpoint (full analysis set) ANCOVA analysis of covariance, CI confidence interval, HbA1c glycosylated hemoglobin, SE standard error, SPC single-pill combination attributed to a higher incidence of mild events of nasopharyngitis, all of which were considered unrelated to the study drug. This is likely a chance finding, given that the only treatment change in this patient was adding placebo treatment to already existing vildagliptin treatment. There were no hypoglycemic events reported in this study, despite the significant improvement in the glycemic control with the SPC, which is consistent with the earlier known safety profile of vildagliptin in Japanese patients with T2DM [14, 15] and a potential vildagliptin mediated protective effect against hypoglycemia through enhanced gastric inhibitory polypeptide [9] . There was no weight gain over 14 weeks of treatment in both the groups reconfirming the previously established weight neutrality effect of metformin [16] . Overall, the safety and tolerability of the vilda/met group were in line with the known safety profile of vildagliptin as a single agent or as a free combination with metformin [10, 14, 15] .
Treatment with SPC of vildagliptin/ metformin targets the multiple pathophysiological abnormalities of T2DM such as impaired insulin secretion, increased endogenous glucose production, and decreased utilization of glucose, in turn helping patients Furthermore, SPC formulations have advantages such as reduced pill burden, improved convenience and adherence over free-dose combinations [17] . Results from a meta-analysis showed that SPC reduces the risk of non-compliance by 26% compared with the free-dose combination [11] .
CONCLUSION
In conclusion, robust glucose-lowering efficacy along with good safety and tolerability makes the vildagliptin/metformin SPC an attractive treatment option for Japanese patients with T2DM who require additional treatment beyond vildagliptin monotherapy.
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